Retatrutide is a synthetic peptide that functions as a triple hormone receptor agonist, targeting the GLP-1, GIP, and glucagon receptors to regulate appetite, improve insulin sensitivity, and increase energy expenditure.
 It is currently undergoing clinical trials for the treatment of obesity and type 2 diabetes, with early results showing significant weight loss and metabolic improvements.
Retatrutide reduces hunger and slows digestion by activating the GLP-1 and GIP receptors, which also help regulate blood sugar levels and improve fat metabolism.
The addition of glucagon receptor activation increases fat and energy burn, promoting greater fat oxidation and energy expenditure compared to single- or dual-agonist drugs.
Clinical trials have demonstrated an average body weight reduction of up to 24.2% over 48 weeks, surpassing the weight loss seen with semaglutide and tirzepatide in head-to-head comparisons.
It is administered as a weekly injection and has shown a safety profile comparable to other GLP-1-based therapies, with gastrointestinal side effects being the most common and dose-related.
Retatrutide is being studied for its potential to improve glycemic control, reduce liver fat, lower triglycerides and LDL cholesterol, and preserve lean muscle mass during weight loss.